Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2089345
Max Phase: Preclinical
Molecular Formula: C32H26ClN5O2
Molecular Weight: 548.05
Molecule Type: Small molecule
Associated Items:
ID: ALA2089345
Max Phase: Preclinical
Molecular Formula: C32H26ClN5O2
Molecular Weight: 548.05
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O[C@@H]1[C@H](O)[C@@H]2C[C@@H]2[C@H]1n1cnc2c(NCc3cccc(Cl)c3)nc(C#Cc3ccc(-c4ccccc4)cc3)nc21
Standard InChI: InChI=1S/C32H26ClN5O2/c33-23-8-4-5-20(15-23)17-34-31-27-32(38(18-35-27)28-24-16-25(24)29(39)30(28)40)37-26(36-31)14-11-19-9-12-22(13-10-19)21-6-2-1-3-7-21/h1-10,12-13,15,18,24-25,28-30,39-40H,16-17H2,(H,34,36,37)/t24-,25+,28+,29+,30-/m0/s1
Standard InChI Key: IHHSUJKYJJRZKL-FZNLZUNPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 548.05 | Molecular Weight (Monoisotopic): 547.1775 | AlogP: 5.07 | #Rotatable Bonds: 5 |
Polar Surface Area: 96.09 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 13.35 | CX Basic pKa: 2.94 | CX LogP: 5.85 | CX LogD: 5.85 |
Aromatic Rings: 5 | Heavy Atoms: 40 | QED Weighted: 0.27 | Np Likeness Score: -0.44 |
1. Tosh DK, Paoletta S, Phan K, Gao ZG, Jacobson KA.. (2012) Truncated Nucleosides as A(3) Adenosine Receptor Ligands: Combined 2-Arylethynyl and Bicyclohexane Substitutions., 3 (7): [PMID:23145215] [10.1021/ml300107e] |
2. Paoletta S, Tosh DK, Finley A, Gizewski ET, Moss SM, Gao ZG, Auchampach JA, Salvemini D, Jacobson KA.. (2013) Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain., 56 (14): [PMID:23789857] [10.1021/jm4007966] |
Source(1):